Mergers & Acquisitions Mergers & Acquisitions

Comment: Illumina, FTC both say lives at stake with Grail deal, but disagree on impact

By Curtis Eichelberger
  • 12 May 2021 15:06
  • 21 Oct 2021 11:09
Illumina and Grail are likely to argue that their merger should be approved by a federal court because it will save lives, while the US Federal Trade Commission will argue that blocking the deal will save lives.
Illumina, a gene sequencing company, is acquiring Grail, a healthcare company with

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News